KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
Last trade$3.53
Day change-$0.16 (-4.34%)
Day range$3.49 – $3.74
Volume81,114
Market cap$160M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$160.05M
Price / earnings
—
Price / book
8.25×
Price / sales
3.46×
EV / sales
3.31×
EV / EBITDA
770.49×
Profitability
Earnings per share
-$0.02
Return on assets
-2.86%
Return on equity
-4.25%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.03×
Current ratio
2.97×
Quick ratio
2.27×
Cash ratio
1.08×
Cash flow
Price / cash flow
361.54×
Price / free cash flow
—
Free cash flow
-$387.37K
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for KRMD, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$11.57M
$12.05M
$11.76M
$10.9M
$10.4M
$10.19M
$9.64M
$8.84M
Cost of revenue
$4.02M
$4.2M
$4.53M
$4.08M
$4.14M
$3.72M
$3.59M
$3.28M
Gross profit
$7.55M
$7.85M
$7.23M
$6.82M
$6.26M
$6.48M
$6.05M
$5.56M
Selling, general and administrative
$5.87M
$5.94M
$6.58M
$6.04M
$5.99M
$5.38M
$5.96M
$5.83M
Research and development
$1.28M
$1.07M
$1.32M
$1.14M
$933.11K
$1.19M
$1.11M
$1.11M
Total operating expenses
$7.36M
$7.22M
$8.1M
$7.36M
$7.13M
$6.79M
$7.29M
$7.15M
Operating income
$187.12K
$626.99K
-$864.92K
-$547.1K
-$867.68K
-$312.66K
-$1.25M
-$1.59M
Interest expense
$60.74K
$59.87K
$81K
$0
$74.57K
$78.95K
$73.18K
$0
Income before taxes
$236.1K
$258.25K
-$807.08K
-$482.17K
-$778.12K
-$189.51K
-$1.17M
-$1.56M
Income taxes
$18K
$5.8K
$0
$4.68K
-$150
$17.36K
$0
$2.89K
Net income
$218.1K
$252.45K
-$807.08K
-$486.86K
-$777.97K
-$206.87K
-$1.17M
-$1.56M
Net income attributable to common shareholders
$218.1K
$252.45K
-$807.08K
-$486.86K
-$777.97K
-$206.87K
-$1.17M
-$1.56M
EBITDA
$397.14K
$837.02K
-$667.39K
-$367.93K
-$663.2K
-$103.17K
-$1.03M
-$1.38M
Basic earnings per share
$0.00
$0.01
-$0.02
-$0.01
-$0.02
$0.00
-$0.03
-$0.03
Diluted earnings per share
$0.00
$0.01
-$0.02
-$0.01
-$0.02
$0.00
-$0.03
-$0.03
Recent news
Company coverage with links to the original publishers.
Doximity (DOCS) is experiencing strong clinical AI adoption with active workflow prescribers up 30% year-over-year and AI Scribe users growing 10-fold, validating its AI capabilities through independent studies. However, the company faces headwinds from modest overall revenue growth (7% YoY), declining gross margins (88% from 91%) due to elevated AI infrastructure costs, and a constrained pharma advertising market. While AI is opening new revenue opportunities, investors await evidence that AI monetization can materially accelerate consolidated growth.
Cirtec Medical has appointed Shar Matin as its new CEO, effective September 2, 2025. Matin brings over 25 years of global leadership experience in medical technology, previously serving as CEO of Cordis and holding executive roles at multiple medical technology companies.
KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 50% and 9.45%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. (CLPT) delivered earnings and revenue surprises of 13.64% and 6.41%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?